» Articles » PMID: 18535022

Central Nervous System Involvement in Anderson-Fabry Disease: a Clinical and MRI Retrospective Study

Overview
Date 2008 Jun 7
PMID 18535022
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Anderson-Fabry disease (AFD) is an X-linked lysosomal storage disorder caused by deficiency of alpha-galactosidase A. Central nervous system (CNS) manifestations consist mainly of cerebrovascular events. Brain MRI results are often abnormal.

Purpose: The aim of the study was to describe CNS involvement in a group of Italian patients with AFD.

Methods: Clinical and brain MRI data of 43 patients with AFD (25 men, 41.94+/-10.83 years old and 18 women, 52.48+/-17.50 years old) were analysed retrospectively. 17 male patients and 7 female patients were under treatment with enzyme replacement therapy (ERT).

Results: All 43 patients had signs or symptoms of AFD. 16 men (64%) and 13 women (72%) demonstrated CNS involvement, although with varying severity. Overall, 6 men and 5 women had suffered from cerebrovascular accidents with an age at onset of 33.64+/-13.65 years and 53.68+/-11.71 years, respectively. Brain MR images were abnormal in 16/25 men and in 13/16 women. During CNS monitoring, some patients receiving ERT (5/17 men and 2/6 women) demonstrated neurological deterioration, especially those who had presented with cerebrovascular disease already before starting ERT.

Conclusions: The study demonstrated a high frequency of CNS involvement in homozygous and heterozygous AFD patients, often characterised by early age at onset and abnormal brain MRIs. At present, ERT is widely used; however, potential beneficent effects may be disguised by the progression of irreversible pathology in short-term follow-up. Therefore, primary and secondary prophylaxes of cerebrovascular disease are extremely important.

Citing Articles

Effects of Current Therapies on Disease Progression in Fabry Disease: A Narrative Review for Better Patient Management in Clinical Practice.

Mignani R, Biagini E, Cianci V, Pieruzzi F, Pisani A, Tuttolomondo A Adv Ther. 2024; 42(2):597-635.

PMID: 39636569 PMC: 11787255. DOI: 10.1007/s12325-024-03041-2.


In Silico Modeling of Fabry Disease Pathophysiology for the Identification of Early Cellular Damage Biomarker Candidates.

Gervas-Arruga J, Barba-Romero M, Fernandez-Martin J, Gomez-Cerezo J, Segu-Verges C, Ronzoni G Int J Mol Sci. 2024; 25(19).

PMID: 39408658 PMC: 11477023. DOI: 10.3390/ijms251910329.


Expanding the Neurological Phenotype of Anderson-Fabry Disease: Proof of Concept for an Extrapyramidal Neurodegenerative Pattern and Comparison with Monogenic Vascular Parkinsonism.

Zedde M, Romani I, Scaravilli A, Cocozza S, Trojano L, Ragno M Cells. 2024; 13(13.

PMID: 38994983 PMC: 11240674. DOI: 10.3390/cells13131131.


SD-OCT Imaging of Macular Changes in Fabry Disease: A Case Report.

Moon S, Ovens C, Reid G, Fraser C Neuroophthalmology. 2024; 48(3):198-203.

PMID: 38756337 PMC: 11095570. DOI: 10.1080/01658107.2024.2301921.


Molecular Pathogenesis of Central and Peripheral Nervous System Complications in Anderson-Fabry Disease.

Tuttolomondo A, Baglio I, Riolo R, Todaro F, Parrinello G, Miceli S Int J Mol Sci. 2024; 25(1).

PMID: 38203231 PMC: 10779326. DOI: 10.3390/ijms25010061.